YiDu Technology won the bid for the Phase III clinical research project of recombinant human nerve growth factor eye drops.

Yidu Technology announced at noon that its subsidiary, Tianjin Happy Life Technology Co., Ltd., has won the bid to reorganize the Phase III clinical research project of Human Nerve Growth Factor Eye Drops of Shandong Yandu Biotechnology Co., Ltd., with a total amount of approximately RMB 55.82 million.